Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILT-123 and TILs in Metastatic Melanoma
NCT04217473Phase 1Completed
- Sponsor
- TILT Biotherapeutics
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of Ad5/3-E2F-D24 in melanoma, sponsored by TILT Biotherapeutics. Primary endpoints: Number of Participants with any (serious and non-serious) Adverse Events prior to TIL administration at 36 days, Number of Participants with abnormal laboratory values prior to TIL administration at 36 days and 2 more. Started Feb 2020; status: completed.
02
Drugs
Ad5/3-E2F-D24
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04217473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217473.